Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Molecular marker for predicting ischemic cardiomyopathy

A technology of ischemic cardiomyopathy and molecular markers, applied in the field of biomedicine, can solve the problems of high mortality, lack of effective and specific diagnosis and treatment methods, etc.

Inactive Publication Date: 2019-09-03
CHANGZHOU NO 2 PEOPLES HOSPITAL
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, the pathogenesis of ischemic cardiomyopathy has not been fully clarified, there is a lack of effective and specific diagnosis and treatment methods, and the mortality rate is high. Therefore, it is particularly important to realize the early diagnosis of ICM

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecular marker for predicting ischemic cardiomyopathy
  • Molecular marker for predicting ischemic cardiomyopathy
  • Molecular marker for predicting ischemic cardiomyopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Q

[0048] Example QPCR detection of expression of EFCC1 or ARHGAP17

[0049] 1. Collect samples

[0050] Left ventricular tissue and blood samples were collected from patients with ischemic cardiomyopathy, and left ventricular tissue and blood samples from patients with non-ischemic cardiomyopathy who died without cardiomyopathy.

[0051] Collection of blood samples: Blood samples were collected from 25 patients with non-ischemic cardiomyopathy and 31 patients with ischemic cardiomyopathy.

[0052] Collection of tissue samples: Left ventricular tissue samples were collected from 21 patients with ischemic cardiomyopathy and from 7 non-cardiomyopathy deaths.

[0053] The ischemic cardiomyopathy group was used as the experimental group, and the non-ischemic cardiomyopathy group was used as the control group.

[0054] 2. RNA extraction

[0055] 2.1 Extraction of tissue RNA

[0056] Use the TRIZOL method to extract tissue RNA, the steps are as follows:

[0057] 1) Shred the tissu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a molecular marker for predicting ischemic cardiomyopathy. The invention discloses the use of the molecular marker EFCC1 or ARHGAP17 in preparation of a product for diagnosingischemic cardiomyopathy, and the invention also discloses a product for diagnosing ischemic cardiomyopathy, the product comprises a reagent for detecting EFCC1 or ARHGAP17. The invention also discloses the use of EFCC1 or ARHGAP17 in constructing a computational model for predicting ischemic cardiomyopathy.

Description

technical field [0001] The invention relates to the field of biomedicine, and relates to a molecular marker for predicting ischemic cardiomyopathy, and the molecular marker is EFCC1 or ARHGAP17. Background technique [0002] Ischemic cardiomyopathy (ICM) is a severe myocardial dysfunction disease caused by coronary artery stenosis and occlusion, chronic myocardial ischemia, and its left ventricular ejection fraction (LVEF) < 40%, accompanied by Multifocal wall motion abnormalities. Myocardial ischemia, degeneration, necrosis and fibrosis caused by multi-vessel coronary artery lesions or diffuse lesions, accompanied by myocardium stun and hibernating myocardium and multifocal wall motion abnormalities, resulting in severe myocardial dysfunction , Spherical enlargement of the heart and heart failure. ICM includes obstruction or narrowing of coronary arteries by atherosclerotic lesions. The common multiple acquired heart diseases in middle-aged and elderly people include ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6883G01N33/68
CPCC12Q1/6883C12Q2600/158G01N33/6893G01N2800/325
Inventor 王庆捷孙铃周学军刘宇
Owner CHANGZHOU NO 2 PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com